Evidence

What is on the record

Figures below are the ones already public. Each block states what it does not yet show.

Growth forecast

The growth algorithm was tested against what a cohort of adolescent faces actually did three years later, then published. Pozzo et al., JPRAS Open 2026;51:485–493.

0.58 mmMean surface deviation, predicted versus observed nose at follow-up.

95.6%Of nasal surface points within 1.5 mm.

2,050Subjects behind the model. Multi-ethnic, ages 6–19, 84 facial landmarks.

This is geometric validation of a forecast. It is not a clinical outcomes trial and it is not regulatory evidence.

Surgical use

250+Patients operated with patient-matched Orthonose guides, produced to order in France.

3Practising rhinoplasty surgeons in Paris, the first paying clients, billed for commercial use.

CE Class I and IIa in Europe; ANSM declaration filed. Patient-specific. US Class I classification. This site does not claim a current FDA listing, clearance, or approval.

Interceptive pilot

At intervention, mean hump growth stopped and diverged from the expected natural rise. Supervised follow-up through the growth window (24–36 months).

4/4Treated. Mean hump change −4 mm² versus an expected +21 mm².

8/8Untreated. Hump growth continued.

Preliminary evidence: a small, non-randomized proof-of-concept series. Larger independent studies and follow-up through nasal maturity are needed.